<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
        xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-news/0.9 http://www.google.com/schemas/sitemap-news/0.9/sitemap-news.xsd http://www.google.com/schemas/sitemap-image/1.1 https://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd">
    <url>
      <loc>https://www.healthcaretimesdenmark.com/article/909371959-zealand-pharma-conference-call-on-may-7-at-2pm-cet-8am-et-to-present-first-quarter-2026-financial-results</loc>
      <news:news>
        <news:publication>
          <news:name>Healthcare Times Denmark</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-30T15:01:00+00:00</news:publication_date>
        <news:title>Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.healthcaretimesdenmark.com/article/909080187-zealand-pharma-and-roche-to-advance-petrelintide-an-amylin-analog-to-phase-3-trials-for-chronic-weight-management</loc>
      <news:news>
        <news:publication>
          <news:name>Healthcare Times Denmark</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-29T17:01:00+00:00</news:publication_date>
        <news:title>Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png</image:loc>
        </image:image>
    </url>
</urlset>
